Vergoeding 2014-2018 voor ATC-subgroep A10AE : Langwerkende insulines voor injectie
- Raming voor de totale Zvw-populatie
| 2014 | 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|---|
| A10AE04 Insuline glargine (Lantus ®) | 47.859.500 | 51.077.700 | 50.254.400 | 46.570.200 | 44.073.600 |
| A10AE05 Insuline detemir (Levemir ®) | 21.842.800 | 21.269.800 | 17.952.900 | 14.745.500 | 12.280.000 |
| A10AE06 Insuline degludec (Tresiba ®) | 27.781 | 901.090 | 7.189.100 | 13.304.900 | 18.564.000 |
| A10AE54 Insuline glargine met lixisenatide (Suliqua ®) | . | . | . | 84.925 | 433.190 |
| A10AE56 Insuline degludec met liraglutide (Xultophy ®) | . | . | . | 1.570.400 | 3.576.300 |
| Totaal | 69.730.081 | 73.248.590 | 75.396.400 | 76.275.925 | 78.927.090 |